What guidance did the company provide for Q3 and full-year 2025 financials, and how does it align with market forecasts? | SCYX (Aug 13, 2025) | Candlesense
SCYX

What guidance did the company provide for Q3 and full-year 2025 financials, and how does it align with market forecasts?

Guidance Overview

Scynexis disclosed that it expects third‑quarter 2025 revenue in the $6.5 million–$7.0 million range and full‑year 2025 revenue of $24 million–$26 million. The company also reiterated its operating‑expense target of roughly $15 million‑$16 million for the year, which translates into an adjusted EBITDA loss of $9 million‑$11 million. For the balance‑sheet, Scynexis reaffirmed its plan to end 2025 with cash and cash equivalents of at least $55 million, sufficient to fund its pipeline through the anticipated Phase III read‑out for its lead anti‑infective candidate.

Alignment with Market Expectations

Consensus forecasts from equity analysts (FactSet/Refinitiv) had been projecting Q3 revenue of $6.4 million‑$7.2 million and full‑year revenue of $23 million‑$27 million, with operating expenses near $15.5 million. Scynexis’ mid‑range guidance sits squarely within these ranges, essentially confirming market expectations. The company’s cash‑runway outlook also matches the “sufficient liquidity” narrative that analysts have been emphasizing, keeping the valuation multiple (EV/Revenue ≈ 12×) stable.

Trading Implications

Because the guidance is broadly in line with consensus, we should not anticipate a sharp price swing on the earnings release itself. However, the reaffirmation of a solid cash position and a clear timeline to a pivotal Phase III read‑out reduces downside risk and makes the stock a candidate for buy‑on‑dip positioning if it experiences a short‑term pull‑back on profit‑taking. Technicals show the stock hovering near its 50‑day EMA with modest upside momentum; a break above the recent high (~$6.20) could trigger a breakout rally, while a breach of the 20‑day EMA (~$5.70) would merit a defensive stop. In short, maintain a neutral‑to‑slightly‑bullish stance, with entry points around current support and upside targets of $6.80–$7.10, reflecting the guidance‑driven upside potential.

Other Questions About This News

How did SCYNEXIS's Q2 2025 revenue and earnings compare to analyst expectations and prior quarter performance? What are the key drivers behind any changes in cash burn or cash runway highlighted in the release? Did the company announce any new clinical trial data, regulatory milestones, or FDA approvals that could affect future revenue? How does SCYNEXIS's current pipeline progress compare to its major competitors in the drug‑resistant infection space? What are the implications of any disclosed licensing, partnership, or financing agreements on the company’s valuation? Are there any upcoming catalysts (e.g., data readouts, regulatory submissions, or partnership announcements) that could move the stock in the short term? What is the status of the company's pipeline candidates, and what timelines were provided for key milestones? How did operating expenses and R&D spend change, and what does that indicate about future investment and profitability? What is the company's current net cash position and burn rate, and how might that impact dilution or financing needs? Did the company provide any updates on market opportunities or competitive positioning for its lead products? How does the sentiment score of 20 influence market perception, and what does it imply about investor sentiment? What are the potential risks or challenges highlighted in the corporate update that could affect future performance?